The safety of celecoxib in patients with aspirin‐sensitive asthma

Authors:
Publisher website
Google Scholar
Abstract
Objective: To determine whether celecoxib, a selective cyclooxygenase 2 (COX‐2) inhibitor, cross‐reacts in patients with aspirin‐exacerbated respiratory disease (AERD) with asthma.Methods: Sixty patients with asthma underwent double‐blinded, placebo‐controlled oral challenges with celecoxib (100 mg, 200 mg, and 2 placebos) over 48 hours in our General Clinical Research Center. The next day, sensitivity to acetylsalicylic acid (ASA) was proven in all patients with the use of single‐blinded ASA challenges.Results: None of the 60 patients experienced any symptoms, changes in nasal examinations, or declines in forced expiratory volume in 1 second during the celecoxib challenges. All 60 patients experienced oculonasal and/or asthmatic reactions to ASA, with a mean provoking dose of 69 mg. The exact 1‐sided confidence interval for the probability of celecoxib inducing cross‐reactions in AERD patients was calculated to be between 0% and 5%.Conclusion: Cross‐reactivity between ASA and celecoxib does not occur in patients with AERD. These results do not preclude the possibility of other types of immune reactions occurring with celecoxib after prior exposure. Our results add to the growing body of evidence that inhibition of COX‐1 is a critical initiating event in the precipitation of respiratory reactions in AERD patients following ingestion of nonsteroidal antiinflammatory drugs.

This publication has 28 references indexed in Scilit: